当前位置: X-MOL 学术Clin. Transl. Immunol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Tocilizumab monotherapy uncovered the role of the CCL22/17‐CCR4+ Treg axis during remission of crescentic glomerulonephritis
Clinical & Translational Immunology ( IF 5.8 ) Pub Date : 2020-10-30 , DOI: 10.1002/cti2.1203
Ryota Sakai 1, 2 , Minako Ito 1 , Keiko Yoshimoto 3 , Shunsuke Chikuma 1 , Takahiko Kurasawa 2 , Tsuneo Kondo 2 , Katsuya Suzuki 3 , Tsutomu Takeuchi 3 , Koichi Amano 2 , Akihiko Yoshimura 1
Affiliation  

Tocilizumab (TCZ) is a humanised anti‐interleukin (IL)‐6 receptor (IL‐6R) monoclonal antibody that is a promising agent to treat various autoimmune diseases. However, the mechanism of TCZ efficacy is unclear. This study aims to elucidate the relationship between Tregs and IL‐6R blockade in autoimmunity‐mediated renal disease based on a TCZ‐treated cohort of patients with anti‐neutrophil cytoplasmic antibody (ANCA)‐associated vasculitis (AAV) and in an experimental model of crescentic glomerulonephritis (cGN).

中文翻译:

托珠单抗单药治疗揭示了 CCL22/17-CCR4+ Treg 轴在新月体肾炎缓解期间的作用

托珠单抗 (TCZ) 是一种人源化抗白细胞介素 (IL)-6 受体 (IL-6R) 单克隆抗体,是治疗各种自身免疫性疾病的有希望的药物。然而,TCZ疗效的机制尚不清楚。本研究旨在阐明 Tregs 和 IL-6R 阻断在自身免疫介导的肾脏疾病中的关系,该研究基于 TCZ 治疗的抗中性粒细胞胞浆抗体 (ANCA) 相关血管炎 (AAV) 患者队列和新月体肾小球肾炎(cGN)。
更新日期:2020-10-30
down
wechat
bug